Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 9, 2015, Pages 5097-5106

  Minato, Yusuke ^a   Thiede, Joshua M ^a   Kordus, Shannon Lynn ^a   McKlveen, Edward J ^b   Turman, Breanna J ^a   Baughn, Anthony D ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; FOLIC ACID; IRON; PRODRUG; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BIOCHEMICAL ANALYSIS; BIOSYNTHESIS; CARBON METABOLISM; DRUG MECHANISM; DRUG TARGETING; FOLATE METABOLISM; GENETIC ANALYSIS; METABOLOMICS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; DRUG EFFECTS; METABOLISM; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANT TUBERCULOSIS;

AMINOSALICYLIC ACID; ANTITUBERCULAR AGENTS; FOLIC ACID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84940907178     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00647-15     Document Type: Review

References (125)

1. World Health Organization. 2013. Global tuberculosis report. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/publications/global-report/en/.
2. East African-British Medical Research Councils. 1974. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. Lancet ii:237-240.
3. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. 2003. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 167: 1472-1477. http://dx.doi.org/10.1164/rccm.200206-626OC.
4. Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney GB, Gomez E, Foresman BH 1994. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 330: 1179-1184. http://dx.doi.org/10.1056/NEJM199404283301702.
5. Ormerod LP. 2005. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. Br Med Bull 73-74:17-24.
6. Zhao Y, Xu S, Wang L, Chin DP, Wang S, Jiang G, Xia H, Zhou Y, Li Q, Ou X, Pang Y, Song Y, Zhao B, Zhang H, He G, Guo J, Wang Y. 2012. National survey of drug-resistant tuberculosis in China. N Engl J Med 366:2161-2170. http://dx.doi.org/10.1056/NEJMoa1108789.
7. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, Jensen P, Bayona J. 2010. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 375:1830-1843. http://dx.doi.org/10.1016/S0140-6736(10)60410-2.
8. Lehmann J. 1946. para-Aminosalicylic acid in the treatment of tuberculosis. Lancet 247:15-16. http://dx.doi.org/10.1016/S0140-6736(46)91185-3.
9. Pfuetze KH, Pyle MM 1949. Streptomycin in the treatment of tuberculosis. JAMA 139:634-639. http://dx.doi.org/10.1001/jama.1949.02900270018005.
10. Youmans GP, Raleigh GW, Youmans AS 1947. The tuberculostatic action of para-aminosalicylic acid. J Bacteriol 54:409-416.
11. Shane SJ, Laurie JH, Riley C, Boutilier M. 1952. Effect of combined therapy (dihydrostreptomycin and PAS)onthe emergenceofstreptomy-cin-resistant strains of tubercle bacilli. N Engl J Med 246:132-134. http://dx.doi.org/10.1056/NEJM195201242460404.
12. Graessle OE, Pietrowski JJ 1949. The in vitro effect of para-aminosalicylic acid (PAS) in preventing acquired resistance to streptomycin by Mycobacterium tuberculosis. J Bacteriol 57:459-464.
13. Anonymous. 1952. Prevention of streptomycin resistance by combined chemotherapy; a Medical Research Council investigation. Br Med J 1:1157-1162. http://dx.doi.org/10.1136/bmj.1.4769.1157.
14. Capon AW. 1954. Streptomycin and PAS vs. streptomycin, PAS and isoniazid in the treatment of pulmonary tuberculosis. Can Med Assoc J 70:62-67.
15. WHO Collaborating Centre for Tuberculosis Chemotherapy. 1976. A comparative study of daily and twice-weekly continuation regimens of tuberculosis chemotherapy, including a comparison of two durations of sanatorium treatment. Tubercle 57:45-48. http://dx.doi.org/10.1016/0041-3879(76)90016-7.
16. Anonymous. 1973. Co-operative controlled trial of a standard regimen of streptomycin, PAS and isoniazid and three alternative regimens of chemotherapy in Britain. A report from the British Medical Research Council. Tubercle 54:99-129.
17. Ferebee SH, Doster BE, Murray FJ 1966. Ethambutol: a substitute for para-aminosalicylic acid in regimens for pulmonary tuberculosis. Ann N Y Acad Sci 135:910-920. http://dx.doi.org/10.1111/j.1749-6632.1966.tb45533.x.
18. Zumla A, Nahid P, Cole ST 2013. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 12: 388-404. http://dx.doi.org/10.1038/nrd4001.
19. Cossins EA. 2000. The fascinating world of folate and one-carbon metabolism. Can J Bot 78:691-708. http://dx.doi.org/10.1139/cjb-78-6-691.
20. Green JG, Matthews RG 2007. Folate biosynthesis, reduction, and polyglutamylation and the interconversion of folate derivatives. EcoSal Plus http://dx.doi.org/10.1128/ecosalplus.3.6.3.6.
21. Bermingham A, Derrick JP 2002. The folic acid biosynthesis pathway in bacteria: evaluation of potential for antibacterial drug discovery. Bioessays 24:637-648. http://dx.doi.org/10.1002/bies.10114.
22. Li R, Sirawaraporn R, Chitnumsub P, Sirawaraporn W, Wooden J, Athappilly F, Turley S, Hol WGJ. 2000. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J Mol Biol 295:307-323. http://dx.doi.org/10.1006/jmbi.1999.3328.
23. Brown GM. 1962. The biosynthesis of folic acid. II. Inhibition by sulfonamides. J Biol Chem 237:536-540.
24. Roland S, Ferone R, Harvey RJ, Styles VL, Morrison RW 1979. The characteristics and significance of sulfonamides as substrates for Escherichia coli dihydropteroate synthase. J Biol Chem 254:10337-10345.
25. Smilack JD. 1999. Trimethoprim-sulfamethoxazole. Mayo Clin Proc 74:730-734. http://dx.doi.org/10.4065/74.7.730.
26. Wormser G, Keusch G, Heel R. 1982. Co-trimoxazole (trimethoprim-sulfamethoxazole). Drugs 24:459-518. http://dx.doi.org/10.2165/00003495-198224060-00002.
27. Ellman P, Lawrence JS, Cumings JN 1941. Investigation in the value of sulphapyridine in the treatment of pulmonary tuberculosis. Tubercle 22:296-302. http://dx.doi.org/10.1016/S0041-3879(41)80057-9.
28. Freilich EB, Coe GC, Wien NA 1939. The use of sulfanilamide in pulmonary tuberculosis: preliminary report. Ann Intern Med 13:1042-1045. http://dx.doi.org/10.7326/0003-4819-13-6-1042.
29. Forgacs P, Wengenack NL, Hall L, Zimmerman SK, Silverman ML, Roberts GD 2009. Tuberculosis and trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 53:4789-4793. http://dx.doi.org/10.1128/AAC.01658-08.
30. Ameen SM, Drancourt M. 2013. In vitro susceptibility of Mycobacterium tuberculosis to trimethoprim and sulfonamides in France. Antimicrob Agents Chemother 57:6370-6371. http://dx.doi.org/10.1128/AAC.01683-13.
31. Vilchèze C, Jacobs WR 2012. The combination of sulfamethoxazole, trimethoprim, and isoniazid or rifampin is bactericidal and prevents the emergence of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 56:5142-5148. http://dx.doi.org/10.1128/AAC.00832-12.
32. Alsaad N, van Altena R, Pranger AD, van Soolingen D, de Lange WCM, van der Werf TS, Kosterink JGW, Alffenaar J-WC. 2013. Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis. Eur Respir J 42:504-512. http://dx.doi.org/10.1183/09031936.00114812.
33. Davies Forsman L, Schön T, Simonsson USH, Bruchfeld J, Larsson M, Juréen P, Sturegård E, Giske CG, Ängeby K. 2014. Intra- and extracellular activities of trimethoprim-sulfamethoxazole against susceptible and multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:7557-7559. http://dx.doi.org/10.1128/AAC.02995-14.
34. Chakraborty S, Gruber T, Barry CE, Boshoff HI, Rhee KY 2013. para-Aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis. Science 339:88-91. http://dx.doi.org/10.1126/science.1228980.
35. Zheng J, Rubin EJ, Bifani P, Mathys V, Lim V, Au M, Jang J, Nam J, Dick T, Walker JR, Pethe K, Camacho LR. 2013. para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis. J Biol Chem 288:23447-23456. http://dx.doi.org/10.1074/jbc.M113.475798.
36. Zhao F, Wang XD, Erber LN, Luo M, Guo AZ, Yang SS, Gu J, Turman BJ, Gao YR, Li DF, Cui ZQ, Zhang ZP, Bi LJ, Baughn AD, Zhang XE, Deng JY. 2014. Binding pocket alterations in dihydrofolate synthase confer resistance to para-aminosalicylic acid in clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:1479-1487. http://dx.doi.org/10.1128/AAC.01775-13.
37. Gerum AB, Ulmer JE, Jacobus DP, Jensen NP, Sherman DR, Sibley CH 2002. Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase. Antimicrob Agents Chemother 46:3362-3369. http://dx.doi.org/10.1128/AAC.46.11.3362-3369.2002.
38. Nixon MR, Saionz KW, Koo MS, Szymonifka MJ, Jung H, Roberts JP, Nandakumar M, Kumar A, Liao R, Rustad T, Sacchettini JC, Rhee KY, Freundlich JS, Sherman DR. 2014. Folate pathway disruption leads to critical disruption of methionine derivatives in Mycobacterium tuberculosis. Chem Biol 21:819-830. http://dx.doi.org/10.1016/j.chembiol.2014.04.009.
39. Ye QZ, Liu J, Walsh CT 1990. p-Aminobenzoate synthesis in Escherichia coli: purification and characterization of PabB as aminodeoxychorismate synthase and enzyme X as aminodeoxychorismate lyase. Proc Natl Acad Sci U S A 87:9391-9395. http://dx.doi.org/10.1073/pnas.87.23.9391.
40. Sassetti CM, Boyd DH, Rubin EJ 2003. Genes required for mycobacterial growth definedby high density mutagenesis. Mol Microbiol 48:77-84. http://dx.doi.org/10.1046/j.1365-2958.2003.03425.x.
41. Griffin JE, Gawronski JD, Dejesus MA, Ioerger TR, Akerley BJ, Sassetti CM 2011. High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. PLoS Pathog 7:e1002251. http://dx.doi.org/10.1371/journal.ppat.1002251.
42. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537-544. http://dx.doi.org/10.1038/31159.
43. Slock J, Stahly DP, Han CY, Six EW, Crawford IP 1990. An apparent Bacillus subtilis folic acid biosynthetic operon containing pab, an amphibolictrpG gene, athird gene required for synthesis ofpara-aminobenzoic acid, and the dihydropteroate synthase gene. J Bacteriol 172:7211-7226.
44. Wolf WA, Brown GM 1969. The biosynthesis of folic acid. X. Evidence for an Amadori rearrangement in the enzymatic formation of dihydroneopterin triphosphate from GTP. Biochim Biophys Acta 192:468-478.
45. Suzuki Y, Brown GM 1974. The biosynthesis of folic acid. XII. Purification and properties of dihydroneopterin triphosphate pyrophosphohydrolase. J Biol Chem 249:2405-2410.
46. Mathis JB, Brown GM 1970. The biosynthesis of folic acid. XI. Purification and properties of dihydroneopterin aldolase. J Biol Chem 245: 3015-3025.
47. Goulding CW, Apostol MI, Sawaya MR, Phillips M, Parseghian A, Eisenberg D. 2005. Regulation by oligomerization in a mycobacterial folate biosynthetic enzyme. J Mol Biol 349:61-72. http://dx.doi.org/10.1016/j.jmb.2005.03.023.
48. Richey DP, Brown GM 1969. The biosynthesis of folic acid. IX. Purification and properties of the enzymes required for the formation of dihydropteroic acid. J Biol Chem 244:1582-1592.
49. Shiota T, Baugh C, Jackson R, Dillard R. 1969. The enzymatic synthesis of hydroxymethyldihydropteridine pyrophosphate and dihydrofolate. Biochemistry 8:5022-5028. http://dx.doi.org/10.1021/bi00840a052.
50. Roback P, Beard J, Baumann D, Gille C, Henry K, Krohn S, Wiste H, Voskuil MI, Rainville C, Rutherford R. 2007. A predicted operon map for Mycobacterium tuberculosis. Nucleic Acids Res 35:5085-5095. http://dx.doi.org/10.1093/nar/gkm518.
51. Caspi R, Foerster H, Fulcher CA, Kaipa P, Krummenacker M, Latendresse M, Paley S, Rhee SY, Shearer AG, Tissier C, Walk TC, Zhang P, Karp PD. 2008. The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases. Nucleic Acids Res 36(Database issue):D623-D631.
52. Gengenbacher M, Xu T, Niyomrattanakit P, Spraggon G, Dick T. 2008. Biochemical and structural characterization of the putative dihydropteroate synthase ortholog Rv1207 of Mycobacterium tuberculosis. FEMS Microbiol Lett 287:128-135. http://dx.doi.org/10.1111/j.1574-6968.2008.01302.x.
53. Baca AM, Sirawaraporn R, Turley S, Sirawaraporn W, Hol WGJ. 2000. Crystal structure of Mycobacterium tuberculosis 6-hydroxymethyl-7,8-dihydropteroate synthase in complex with pterin monophosphate: new insight into the enzymatic mechanism and sulfa-drug action. J Mol Biol 302:1193-1212. http://dx.doi.org/10.1006/jmbi.2000.4094.
54. Young PG, Smith CA, Metcalf P, Baker EN 2008. Structures of Mycobacterium tuberculosis folylpolyglutamate synthase complexed with ADP and AMPPCP. Acta Crystallogr D Biol Crystallogr D64(Pt 7):745-753. http://dx.doi.org/10.1107/S0907444908012262.
55. Bognar AL, Shane B. 1986. Bacterial folylpoly(gamma-glutamate) synthase-dihydrofolate synthase. Methods Enzymol 122:349-359. http://dx.doi.org/10.1016/0076-6879(86)22193-X.
56. Lawrence SA, Titus SA, Ferguson J, Heineman AL, Taylor SM, Moran RG 2014. Mammalian mitochondrial and cytosolic folylpolyglutamate synthetase maintain the subcellular compartmentalization of folates. J Biol Chem 289:29386-29396. http://dx.doi.org/10.1074/jbc.M114.593244.
57. Whitfield CD, Steers EJ, Weissbach H. 1970. Purification and properties of 5-methyltetrahydropteroyltriglutamate-homocysteine transmethylase. J Biol Chem 245:390-401.
58. Blakley RL, MacDougall BM 1961. Dihydrofolic reductase from Streptococcus faecalis R. J Biol Chem 236:1163-1167.
59. Dias MVB, Tyrakis P, Domingues RR, Leme AFP, Blundell TL 2014. Mycobacterium tuberculosis dihydrofolate reductase reveals two conformational states and a possible low affinity mechanism to antifolate drugs. Structure 22:94-103. http://dx.doi.org/10.1016/j.str.2013.09.022.
60. Nopponpunth V, Sirawaraporn W, Greene PJ, Santi DV 1999. Cloning and expression of Mycobacterium tuberculosis and Mycobacterium leprae dihydropteroate synthase in Escherichia coli. J Bacteriol 181:6814-6821.
61. McCullough JL, Maren TH 1973. Inhibition of dihydropteroate synthetase from Escherichia coli by sulfones and sulfonamides. Antimicrob Agents Chemother 3:665-669. http://dx.doi.org/10.1128/AAC.3.6.665.
62. Allegra CJ, Boarman D, Kovacs JA, Morrison P, Beaver J, Chabner BA, Masur H. 1990. Interaction ofsulfonamide and sulfone compounds with Toxoplasma gondii dihydropteroate synthase. J Clin Invest 85:371-379. http://dx.doi.org/10.1172/JCI114448.
63. Triglia T, Menting JGT, Wilson C, Cowman AF 1997. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A 94: 13944-13949. http://dx.doi.org/10.1073/pnas.94.25.13944.
64. Kasekarn W, Sirawaraporn R, Chahomchuen T, Cowman AF, Sirawaraporn W. 2004. Molecular characterization of bifunctional hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase from Plasmodium falciparum. Mol Biochem Parasitol 137:43-53. http://dx.doi.org/10.1016/j.molbiopara.2004.04.012.
65. Voeller D, Kovacs J, Andrawis V, Chu E, Masur H, Allegra C. 1994. Interaction of Pneumocystis carinii dihydropteroate synthase with sulfonamides and diaminodiphenyl sulfone (dapsone). J Infect Dis 169: 456-459. http://dx.doi.org/10.1093/infdis/169.2.456.
66. Wallace RJ, Nash DR, Steele LC, Steingrube V. 1986. Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth. J Clin Microbiol 24:976-981.
67. Britton WJ, Lockwood DN 2004. Leprosy. Lancet 363:1209-1219. http://dx.doi.org/10.1016/S0140-6736(04)15952-7.
68. Poe M, Breeze AS, Wu JK, Short CR, Hoogsteen K. 1979. Dihydrofolate reductase from trimethoprim-resistant Escherichia coli MB 3746 and MB 3747. Purification, amino acid composition, and some kinetic properties. J Biol Chem 254:1799-1805.
69. White EL, Ross LJ, Cunningham A, Escuyer V. 2004. Cloning, expression, and characterization of Mycobacterium tuberculosis dihydrofolate reductase. FEMS Microbiol Lett 232:101-105. http://dx.doi.org/10.1016/S0378-1097(04)00038-2.
70. Huang T-S, Kunin CM, Yan B-S, Chen Y-S, Lee SS-J, Syu W. 2012. Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a 12 year period in Taiwan. J Antimicrob Chemother 67:633-637. http://dx.doi.org/10.1093/jac/dkr501.
71. Suling WJ, Reynolds RC, Barrow EW, Wilson LN, Piper JR, Barrow WW 1998. Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase. J Antimicrob Chemother 42:811-815. http://dx.doi.org/10.1093/jac/42.6.811.
72. Ogwang S, Nguyen HT, Sherman M, Bajaksouzian S, Jacobs MR, Boom WH, Zhang G-F, Nguyen L. 2011. Bacterial conversion of folinic acid is required for antifolate resistance. J Biol Chem 286:15377-15390. http://dx.doi.org/10.1074/jbc.M111.231076.
73. Wolff KA, Nguyen L. 2012. Strategies for potentiation of ethionamide and folate antagonists against Mycobacterium tuberculosis. Expert Rev Anti Infect Ther 10:971-981. http://dx.doi.org/10.1586/eri.12.87.
74. El-Hamamsy MHRI, Smith AW, Thompson AS, Threadgill MD 2007. Structure-based design, synthesis and preliminary evaluation of selective inhibitors of dihydrofolate reductase from Mycobacterium tuberculosis. Bioorg Med Chem 15:4552-4576. http://dx.doi.org/10.1016/j.bmc.2007.04.011.
75. Kumar A, Zhang M, Zhu L, Liao RP, Mutai C, Hafsat S, Sherman DR, Wang M-W. 2012. High-throughput screening and sensitized bacteria identify an M. tuberculosis dihydrofolate reductase inhibitor with whole cell activity. PLoS One 7:e39961. http://dx.doi.org/10.1371/journal.pone.0039961.
76. Childs G, Lambros C. 1986. Analogues of N-benzyloxydihydrotriazines: in vitro antimalarial activity against Plasmodium falciparum. Ann Trop Med Parasitol 80:177-181.
77. Meyer SC, Majumder SK, Cynamon MH 1995. In vitro activities of PS-15, a new dihydrofolate reductase inhibitor, and its cyclic metabolite against Mycobacterium avium complex. Antimicrob Agents Chemother 39:1862-1863. http://dx.doi.org/10.1128/AAC.39.8.1862.
78. Shah LM, DeStefano MS, Cynamon MH 1996. Enhanced in vitro activity of WR99210 in combination with dapsone against Mycobacterium avium complex. Antimicrob Agents Chemother 40:2644-2645.
79. Bernheim F. 1940. The effect of salicylate on the oxygen uptake of the tubercle bacillus. Science 92:204. http://dx.doi.org/10.1126/science.92.2383.204-a.
80. Bernheim F. 1941. The effect of various substances on the oxygen uptake of the tubercle bacillus. J Bacteriol 41:387-395.
81. Hedgecock LW. 1956. Antagonism of the inhibitory action of aminosaliylic acid on Mycobacterium tuberculosisby methionine, biotin and certain fatty acids, amino acids, and purines. J Bacteriol 72:839-846.
82. Hedgecock LW. 1958. Antagonism of methionine in aminosalicylate-inhibition of Mycobacterium tuberculosis. J Bacteriol 75:417-421.
83. Rengarajan J, Sassetti CM, Naroditskaya V, Sloutsky A, Bloom BR, Rubin EJ 2004. The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria. Mol Microbiol 53:275-282. http://dx.doi.org/10.1111/j.1365-2958.2004.04120.x.
84. Yegian D, Long RT 1951. The specific resistance of tubercle bacilli to para-aminosalicylic acid and sulfonamides. J Bacteriol 61:747-749.
85. Xie Z, Siddiqi N, Rubin EJ 2005. Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 49:4778-4780. http://dx.doi.org/10.1128/AAC.49.11.4778-4780.2005.
86. Hawser S, Lociuro S, Islam K. 2006. Dihydrofolate reductase inhibitors as antibacterial agents. Biochem Pharmacol 71:941-948. http://dx.doi.org/10.1016/j.bcp.2005.10.052.
87. Cohen SS, Barner HD 1954. Studies on unbalanced growth in Escherichia coli. Proc Natl Acad Sci U S A 40:885-893. http://dx.doi.org/10.1073/pnas.40.10.885.
88. Then R, Angehrn P. 1973. Sulphonamide-induced 'thymineless death' in Escherichia coli. J Gen Microbiol 76:255-263. http://dx.doi.org/10.1099/00221287-76-2-255.
89. Ahmad SI, Kirk SH, Eisenstark A. 1998. Thymine metabolism and thymineless death in prokaryotes and eukaryotes. Annu Rev Microbiol 52:591-625. http://dx.doi.org/10.1146/annurev.micro.52.1.591.
90. Barclay B, Little JG 1978. Genetic damage during thymidylate starvation in Saccharomyces cerevisiae. Mol Gen Genet 160:33-40.
91. Yamao F, Nagai Y, Kaneda S, Yoshida S, Seno T. 1993. Conditional resistance to thymineless death predominantly selects DNA synthesisdeficient mutants of mammalian cells. Mutat Res 289:83-89. http://dx.doi.org/10.1016/0027-5107(93)90133-Z.
92. Breitman TR, Maury PB, Toal JN 1972. Loss of deoxyribonucleic acid-thymine during thymine starvation of Escherichia coli. J Bacteriol 112:646-648.
93. Freifelder D, Katz G. 1971. Persistence of small fragments of newly synthesized DNA in bacteria following thymidine starvation. J Mol Biol 57:351-354. http://dx.doi.org/10.1016/0022-2836(71)90351-2.
94. Yoshinaga K. 1973. Double-strand scission of DNA involved in thymineless death of Escherichia coli 15 TAU. Biochim Biophys Acta 294: 204-213. http://dx.doi.org/10.1016/0005-2787(73)90293-1.
95. Parveen N, Cornell KA 2011. Methylthioadenosine/S-adenosylhomocysteine nucleosidase, a critical enzyme for bacterial metabolism. Mol Microbiol 79:7-20. http://dx.doi.org/10.1111/j.1365-2958.2010.07455.x.
96. Rahman A, Srivastava S, Sneh A, Ahmed N, Krishnasastry M. 2010. Molecular characterization of tlyA gene product, Rv1694 of Mycobacterium tuberculosis: a non-conventional hemolysin and a ribosomal RNA methyl transferase. BMC Biochem 11:35. http://dx.doi.org/10.1186/1471-2091-11-35.
97. Boissier F, Bardou F, Guillet V, Uttenweiler-Joseph S, Daffé M, Quémard A, Mourey L. 2006. Further insight into S-adenosylmethionine-dependent methyltransferases: structural characterization of Hma, an enzyme essential for the biosynthesis of oxygenated mycolic acids in Mycobacterium tuberculosis. J Biol Chem 281:4434-4445. http://dx.doi.org/10.1074/jbc.M510250200.
98. Cornell KA, Primus S, Martinez JA, Parveen N. 2009. Assessment of methylthioadenosine/S-adenosylhomocysteine nucleosidases of Borrelia burgdorferi as targets for novel antimicrobials using a novel high-throughput method. J Antimicrob Chemother 63:1163-1172. http://dx.doi.org/10.1093/jac/dkp129.
99. Fivian-Hughes AS, Houghton J, Davis EO 2012. Mycobacterium tuberculosis thymidylate synthase gene thyXis essential and potentially bifunctional, while thyA deletion confers resistance to p-aminosalicylic acid. Microbiology 158:308-318. http://dx.doi.org/10.1099/mic.0.053983-0.
100. Nguyen L, Thompson CJ 2006. Foundations of antibiotic resistance in bacterial physiology: the mycobacterial paradigm. Trends Microbiol 14: 304-312. http://dx.doi.org/10.1016/j.tim.2006.05.005.
101. Nagachar N, Ratledge C. 2010. Knocking out salicylate biosynthesis genes in Mycobacterium smegmatis induces hypersensitivity to p-aminosalicylate (PAS). FEMS Microbiol Lett 311:193-199. http://dx.doi.org/10.1111/j.1574-6968.2010.02091.x.
102. Ratledge C, Brown KA 1972. Inhibition of mycobactin formation in Mycobacterium smegmatis by p-aminosalicylate. A new proposal for the mode of action of p-aminosalicylate. Am Rev Respir Dis 106:774-776.
103. Adilakshmi T, Ayling PD, Ratledge C. 2000. Mutational analysis of a role for salicylic acid in iron metabolism of Mycobacterium smegmatis. J Bacteriol 182:264-271. http://dx.doi.org/10.1128/JB.182.2.264-271.2000.
104. Snow GA. 1965. Isolation and structure of mycobactin T, a growth factor from Mycobacterium tuberculosis. Biochem J 97:166-175.
105. Lane SJ, Marshall PS, Upton RJ, Ratledge C, Ewing M. 1995. Novel extracellular mycobactins, the carboxymycobactins from Mycobacterium avium. Tetrahedron Lett 36:4129-4132. http://dx.doi.org/10.1016/0040-4039(95)00676-4.
106. Gobin J, Moore CH, Reeve JR, Wong DK, Gibson BW, Horwitz MA 1995. Iron acquisition by Mycobacterium tuberculosis: isolation and characterization of a family of iron-binding exochelins. Proc Natl Acad Sci U S A 92:5189-5193. http://dx.doi.org/10.1073/pnas.92.11.5189.
107. Brown KA, Ratledge C. 1975. The effect of p-aminosalicyclic acid on iron transport and assimilation in mycobacteria. Biochim Biophys Acta 385:207-220. http://dx.doi.org/10.1016/0304-4165(75)90349-9.
108. Kopinc R, Lapanje A. 2012. Antibiotic susceptibility profile of Mycobacterium avium subspecies hominissuis is altered in low-iron conditions. J Antimicrob Chemother 67:2903-2907. http://dx.doi.org/10.1093/jac/dks313.
109. Schaller A, Sun Z, Yang Y, Somoskovi A, Zhang Y. 2002. Salicylate reduces susceptibility of Mycobacterium tuberculosis to multiple antituberculosis drugs. Antimicrob Agents Chemother 46:2636-2639. http://dx.doi.org/10.1128/AAC.46.8.2636-2639.2002.
110. De Voss JJ, Rutter K, Schroeder BG, Su H, Zhu Y, Barry CE 2000. The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages. Proc Natl Acad Sci U S A 97:1252-1257. http://dx.doi.org/10.1073/pnas.97.3.1252.
111. Turnbull FW, Wallace AT, Stewart S, Crofton JW 1953. Streptomycin resistance in patients with pulmonary tuberculosis previously treated with PAS alone. Br Med J 1:1244-1246. http://dx.doi.org/10.1136/bmj.1.4822.1244.
112. Myllykallio H, Lipowski G, Leduc D, Filee J, Forterre P, Liebl U. 2002. An alternative flavin-dependent mechanism for thymidylate synthesis. Science 297:105-107. http://dx.doi.org/10.1126/science.1072113.
113. Chernyshev A, Fleischmann T, Kohen A. 2007. Thymidyl biosynthesis enzymes as antibiotic targets. Appl Microbiol Biotechnol 74:282-289. http://dx.doi.org/10.1007/s00253-006-0763-1.
114. Kok M, Bühlmann E, Pechère JC. 2001. Salmonella typhimurium thyA mutants fail to grow intracellularly in vitro and are attenuated in mice. Microbiology 147(Pt 3):727-733.
115. Cersini A, Salvia AM, Bernardini ML 1998. Intracellular multiplication and virulence of Shigella flexneri auxotrophic mutants. Infect Immun 66:549-557.
116. Mathys V, Wintjens R, Lefevre P, Bertout J, Singhal A, Kiass M, Kurepina N, Wang XM, Mathema B, Baulard A, Kreiswirth BN, Bifani P. 2009. Molecular genetics of para-aminosalicylic acid resistancein clinical isolates and spontaneous mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother 53:2100-2109. http://dx.doi.org/10.1128/AAC.01197-08.
117. Leung KL, Yip CW, Yeung YL, Wong KL, Chan WY, Chan MY, Kam KM 2010. Usefulness of resistant gene markers for predicting treatment outcome on second-line anti-tuberculosis drugs. J Appl Microbiol 109: 2087-2094. http://dx.doi.org/10.1111/j.1365-2672.2010.04840.x.
118. Zhang X, Liu L, Zhang Y, Dai G, Huang H, Jin Q. 2015. Genetic determinants involved in p-aminosalicylic acid resistance in clinical isolates from tuberculosis patients in northern China from 2006 to 2012. Antimicrob Agents Chemother 59:1320-1324. http://dx.doi.org/10.1128/AAC.03695-14.
119. Li XZ, Nikaido H. 2009. Efflux-mediated drug resistance in bacteria: an update. Drugs 69:1555-1623. http://dx.doi.org/10.2165/11317030-000000000-00000.
120. Black PA, Warren RM, Louw GE, van Helden PD, Victor TC, Kana BD 2014. Energy metabolism and drug efflux in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:2491-2503. http://dx.doi.org/10.1128/AAC.02293-13.
121. Ramón-García S, Mick V, Dainese E, Martín C, Thompson CJ, De Rossi E, Manganelli R, Aínsa JA. 2012. Functional and genetic characterization of the tap efflux pump in Mycobacterium bovis BCG. Antimicrob Agents Chemother 56:2074-2083. http://dx.doi.org/10.1128/AAC.05946-11.
122. Siddiqi N, Das R, Pathak N, Banerjee S, Ahmed N, Katoch VM, Hasnain SE 2004. Mycobacterium tuberculosis isolate with a distinct genomic identity overexpresses a Tap-like efflux pump. Infection 32: 109-111. http://dx.doi.org/10.1007/s15010-004-3097-x.
123. Calgin MK, Sahin F, Turegun B, Gerceker D, Atasever M, Koksal D, Karasartova D, Kiyan M. 2013. Expression analysis of efflux pump genes among drug-susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates and reference strains. Diagn Microbiol Infect Dis 76:291-297. http://dx.doi.org/10.1016/j.diagmicrobio.2013.02.033.
124. Schuessler DL, Parish T. 2012. The promoter of Rv0560c is induced by salicylate and structurally-related compounds in Mycobacterium tuberculosis. PLoS One 7:e34471. http://dx.doi.org/10.1371/journal.pone.0034471.
125. Sun Z, Cheng S-J, Zhang H, Zhang Y. 2001. Salicylate uniquely induces a 27-kDa protein in tubercle bacillus. FEMS Microbiol Lett 203:211-216. http://dx.doi.org/10.1111/j.1574-6968.2001.tb10843.x.